Jennifer leverages diverse scientific and professional expertise in the biomedical sciences to help clients develop and manage strategic patent portfolios. She works with a variety of pharmaceutical, biotechnology, and academic clients to draft and prosecute patent applications.
Prior to joining the firm, Jennifer completed a postdoctoral fellowship at the biopharmaceutical company AbbVie, where she investigated diagnostic safety biomarkers and novel tools to predict male reproductive toxicity during drug discovery and development. As a postdoctoral fellow at the U.S. Food and Drug Administration, she gained experience in regulatory science by supporting the evaluation of nonclinical and clinical data to assess the safety and efficacy of potentially therapeutic substances nominated for use in pharmacy compounding.
During her doctoral research at the Mayo Clinic, Jennifer explored mechanisms of cancer cell death induced by novel small molecules, and employed a transgenic mouse model of B cell lymphoma to study cell cycle regulation by an endoplasmic reticulum protein. As a molecular biologist, she specialized in a wide range of biochemical and cell biology methods, including cell-based screening assays, confocal microscopy, cytotoxicity assays, flow cytometry, gene silencing, immunoassays, RNA sequencing, and target identification studies.
Jennifer has authored and co-authored original research articles in peer-reviewed journals, including Blood, Cancer Biology & Therapy, Cell Death Discovery, and Molecular and Cellular Biology.
- Oak Ridge Institute for Science and Education Fellow, U.S. Food and Drug Administration
- Ralph M. Barford Fellowship, Mayo Clinic Graduate School of Biomedical Sciences
- Research Opportunity Program Award, University of Toronto
- Howard Ferguson Provincial Scholarship, University of Toronto
- Member, American College of Toxicology
- Member, American Intellectual Property Law Association